Clinical Trial Update: Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating initial therapy with Umbralisib plus Rituximab for Follicular Lymphoma and Marginal Zone Lymphoma was terminated, with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Marginal Zone Lymphoma

Drugs mentioned

• Rituximab (rituximab)
• umbralisib

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Lymphoma, Follicular Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2026-02-27